Apoptosis Induction and Anti-cancer Activity of LeciPlex Formulations

Overview

Journal Cell Oncol (Dordr)

Publisher Springer

Date 2014 Sep 11

PMID 25204961

Citations 3

Authors

Vivek V Dhawan

Ganesh V Joshi

Ankitkumar S Jain

Yuvraj P Nikam

Rajiv P Gude

Rita Mulherkar

Mangal S Nagarsenker

Affiliations

Soon will be listed here.

Abstract

Purpose: Cationic agents have been reported to possess anti-neoplastic properties against various cancer cell types. However, their complexes with lipids appear to interact differently with different cancer cells. The purpose of this study was to (i) design and generate novel cationic lecithin nanoparticles, (ii) assess and understand the mechanism underlying their putative cytotoxicity and (iii) test their effect on cell cycle progression in various cancer-derived cell lines. In addition, we aimed to evaluate the in vivo potential of these newly developed nanoparticles in oral anti-cancer delivery.

Methods: Cationic lecithin nanoparticles were generated using a single step nanoprecipitation method and they were characterized for particle size, zeta potential, stability and in vitro release. Their cytotoxic potential was assessed using a sulforhodamine B assay, and their effect on cell cycle progression was evaluated using flow cytometry. The nanoparticle systems were also tested in vivo for their anti-tumorigenic potential.

Results: In contrast to cationic agents alone, the newly developed nanoformulations showed a specific toxicity against cancer cells. The mechanism of toxic cell death included apoptosis, S and G2/M cell cycle phase arrest, depending on the type of cationic agent and the cancer-derived cell line used. Both blank and drug-loaded systems exhibited significant anti-cancer activity, suggesting a synergistic anti-tumorigenic effect of the drug and its delivery system.

Conclusions: Both in vitro and in vivo data indicate that cationic agents themselves exhibit broad anti-neoplastic activities. Complex formation of the cationic agents with phospholipids was found to provide specificity to the anti-cancer activity. These formulations thus possess potential for the design of effective anti-cancer delivery systems.

Citing Articles

Recurrent UBE3C-LRP5 translocations in head and neck cancer with therapeutic implications.

Dharavath B, Butle A, Chaudhary A, Pal A, Desai S, Chowdhury A NPJ Precis Oncol. 2024; 8(1):63.

PMID: 38438481 PMC: 10912599. DOI: 10.1038/s41698-024-00555-4.

Spironolactone-Loaded LeciPlexes as Potential Topical Delivery Systems for Female Acne: In Vitro Appraisal and Ex Vivo Skin Permeability Studies.

Salama A, Badran M, Elmowafy M, Soliman G Pharmaceutics. 2019; 12(1).

PMID: 31881783 PMC: 7022583. DOI: 10.3390/pharmaceutics12010025.

Metformin and epithelial ovarian cancer therapeutics.

Patel S, Kumar L, Singh N Cell Oncol (Dordr). 2015; 38(5):365-75.

PMID: 26266765 DOI: 10.1007/s13402-015-0235-7.

References

Liang C, Chou T . Effect of chain length on physicochemical properties and cytotoxicity of cationic vesicles composed of phosphatidylcholines and dialkyldimethylammonium bromides. Chem Phys Lipids. 2009; 158(2):81-90. DOI: 10.1016/j.chemphyslip.2009.01.006. View

Psahoulia F, Drosopoulos K, Doubravska L, Andera L, Pintzas A . Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts. Mol Cancer Ther. 2007; 6(9):2591-9. DOI: 10.1158/1535-7163.MCT-07-0001. View

Jain A, Shah S, Nagarsenker M, Nikam Y, Gude R, Steiniger F . Lipid colloidal carriers for improvement of anticancer activity of orally delivered quercetin: formulation, characterization and establishing in vitro-in vivo advantage. J Biomed Nanotechnol. 2013; 9(7):1230-40. DOI: 10.1166/jbn.2013.1636. View

Kusumoto K, Ishikawa T . Didodecyldimethylammonium bromide (DDAB) induces caspase-mediated apoptosis in human leukemia HL-60 cells. J Control Release. 2010; 147(2):246-52. DOI: 10.1016/j.jconrel.2010.07.114. View

Carbone C, Tomasello B, Ruozi B, Renis M, Puglisi G . Preparation and optimization of PIT solid lipid nanoparticles via statistical factorial design. Eur J Med Chem. 2012; 49:110-7. DOI: 10.1016/j.ejmech.2012.01.001. View

Vlachy N, Touraud D, Heilmann J, Kunz W . Determining the cytotoxicity of catanionic surfactant mixtures on HeLa cells. Colloids Surf B Biointerfaces. 2009; 70(2):278-80. DOI: 10.1016/j.colsurfb.2008.12.038. View

Bramer T, Dew N, Edsman K . Catanionic mixtures involving a drug: a rather general concept that can be utilized for prolonged drug release from gels. J Pharm Sci. 2006; 95(4):769-80. DOI: 10.1002/jps.20582. View

Liu H, Yu D, Shin S, Park H, Park J, Bark K . Spectroscopic properties of quercetin derivatives, quercetin-3-O-rhamnoside and quercetin-3-O-rutinoside, in hydro-organic mixed solvents. Photochem Photobiol. 2009; 85(4):934-42. DOI: 10.1111/j.1751-1097.2009.00550.x. View

Ito E, Yip K, Katz D, Fonseca S, Hedley D, Chow S . Potential use of cetrimonium bromide as an apoptosis-promoting anticancer agent for head and neck cancer. Mol Pharmacol. 2009; 76(5):969-83. DOI: 10.1124/mol.109.055277. View

10.

Chen S, Nien S, Wu C, Liu C, Chang Y, Lin Y . Reappraisal of the anticancer efficacy of quercetin in oral cancer cells. J Chin Med Assoc. 2013; 76(3):146-52. DOI: 10.1016/j.jcma.2012.11.008. View

11.

Yan-Yu X, Yun-mei S, Zhi-peng C, Qi-neng P . Preparation of silymarin proliposome: a new way to increase oral bioavailability of silymarin in beagle dogs. Int J Pharm. 2006; 319(1-2):162-8. DOI: 10.1016/j.ijpharm.2006.03.037. View

12.

Kretzer I, Maria D, Maranhao R . Drug-targeting in combined cancer chemotherapy: tumor growth inhibition in mice by association of paclitaxel and etoposide with a cholesterol-rich nanoemulsion. Cell Oncol (Dordr). 2012; 35(6):451-60. DOI: 10.1007/s13402-012-0104-6. View

13.

Carbone C, Campisi A, Manno D, Serra A, Spatuzza M, Musumeci T . The critical role of didodecyldimethylammonium bromide on physico-chemical, technological and biological properties of NLC. Colloids Surf B Biointerfaces. 2014; 121:1-10. DOI: 10.1016/j.colsurfb.2014.05.024. View

14.

Fangueiro J, Andreani T, Egea M, Garcia M, Souto S, Silva A . Design of cationic lipid nanoparticles for ocular delivery: development, characterization and cytotoxicity. Int J Pharm. 2013; 461(1-2):64-73. DOI: 10.1016/j.ijpharm.2013.11.025. View

15.

Mulherkar R, Goud A, Wagle A, Naresh K, Mahimkar M, Thomas S . Establishment of a human squamous cell carcinoma cell line of the upper aero-digestive tract. Cancer Lett. 1997; 118(1):115-21. DOI: 10.1016/s0304-3835(97)00241-3. View

16.

Yuan Z, Chen L, Fan L, Tang M, Yang G, Yang H . Liposomal quercetin efficiently suppresses growth of solid tumors in murine models. Clin Cancer Res. 2006; 12(10):3193-9. DOI: 10.1158/1078-0432.CCR-05-2365. View

17.

Doktorovova S, Shegokar R, Rakovsky E, Gonzalez-Mira E, Lopes C, Silva A . Cationic solid lipid nanoparticles (cSLN): structure, stability and DNA binding capacity correlation studies. Int J Pharm. 2011; 420(2):341-9. DOI: 10.1016/j.ijpharm.2011.08.042. View

18.

Anand B, Romero J, Sanduja S, Lichtenberger L . Phospholipid association reduces the gastric mucosal toxicity of aspirin in human subjects. Am J Gastroenterol. 1999; 94(7):1818-22. DOI: 10.1111/j.1572-0241.1999.01211.x. View

19.

Nifli A, Theodoropoulos P, Munier S, Castagnino C, Roussakis E, Katerinopoulos H . Quercetin exhibits a specific fluorescence in cellular milieu: a valuable tool for the study of its intracellular distribution. J Agric Food Chem. 2007; 55(8):2873-8. DOI: 10.1021/jf0632637. View

20.

Khumsupan P, Ramirez R, Khumsupan D, Narayanaswami V . Apolipoprotein E LDL receptor-binding domain-containing high-density lipoprotein: a nanovehicle to transport curcumin, an antioxidant and anti-amyloid bioflavonoid. Biochim Biophys Acta. 2010; 1808(1):352-9. PMC: 2997894. DOI: 10.1016/j.bbamem.2010.09.007. View